Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565381 · ClinicalTrials.gov registry record · NA
A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care for Homeless Smokers
A NA study of Smoking, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT02565381: Completed NA study of Smoking, sponsored by Massachusetts General Hospital.
NCT02565381 is a NA study of Smoking that has completed, run by Massachusetts General Hospital. The registered enrollment target is 83 participants, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02565381, a NA study of Smoking, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
The QUIT (Quitting with Usual Care, Incentives, and Technology) Smoking Study is a 3-arm pilot randomized controlled trial that will test the effect of 2 different experimental smoking cessation interventions relative to a control condition in homeless cigarette smokers. All participants will receive free transdermal nicotine patches and weekly in-person smoking cessation counseling. In addition, participants randomized to the first experimental condition will receive financial rewards for biochemically-verified smoking abstinence, and participants randomized to the second experimental condition will be enrolled in a text messaging program to support smoking abstinence.
Primary Outcome
The primary outcome is a repeated-measures assessment of smoking abstinence, defined as an exhaled carbon monoxide \<8ppm and assessed 14 times over the 8-week study period (3 times/week for the first 2 weeks, 2 times/week for the next 2 weeks, and once every week for the last 4 weeks)
Conditions Studied
Interventions
- DRUG Transdermal nicotine patch
- BEHAVIORAL In-person smoking cessation counseling
- BEHAVIORAL Contingent financial rewards for smoking abstinence
- BEHAVIORAL Text messages to support smoking abstinence
Study Locations (1)
Massachusetts
- Boston Health Care for the Homeless Program - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-08 |
| Phase | NA |
What the finished NCT02565381 record still lists
NCT02565381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 4 interventions - of which Transdermal nicotine patch is the first listed.
NCT02565381 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02565381 about?
NCT02565381 is a clinical study titled "A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care for Homeless Smokers". The QUIT (Quitting with Usual Care, Incentives, and Technology) Smoking Study is a 3-arm pilot randomized controlled trial that will test the effect of 2 different experimental smoking cessation interventions relative to a control condition in homeless cigarette smokers. All participants will receiv...
What is the current status of trial NCT02565381?
This trial is currently completed. It is a NA study. The enrollment target is 83 participants. The study started on 2015-10. Estimated completion is 2016-08.
What conditions does trial NCT02565381 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT02565381?
The interventions under investigation include: Transdermal nicotine patch (DRUG), In-person smoking cessation counseling (BEHAVIORAL), Contingent financial rewards for smoking abstinence (BEHAVIORAL), Text messages to support smoking abstinence (BEHAVIORAL).
Who is sponsoring clinical trial NCT02565381?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02565381 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02565381's enrollment target sits among peer trials
83 83rd of 123 higher than 41 of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Alternatives for Reducing Harm Using E-cigarettes
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer Type
RECRUITING · NA
-
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
RECRUITING · NA
-
Take A Break - Rural
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia